Menopausal syndrome as the first clinical manifestation of perimenopause
DOI:
https://doi.org/10.18370/2309-4117.2015.21.52-56Keywords:
climacteric syndrome, perimenopause, Kleverol, red cloverAbstract
A study to examine the efficacy and safety of drug Kleverol (active ingredient is a red clover) in patients with climacteric disorders of mild to moderate severity in late reproductive period was performed.
40 patients aged 36–49 years with climacteric disorders of mild to moderate severity were observed. Kleverol was administered 1 capsule a day for 3 months.
The average menopausal index, according to a Menopause Rating Scale (MRS), was significantly lower after treatment (8,7 ± 0,3) than before treatment (22,2 ± 0,3). In all examined women hormone levels corresponded to perimenopausal values. Side effects and individual intolerance reactions were not observed.
Authors of the study conclude that a good level of efficacy and safety Kleverol allows to use it at the earliest manifestations of menopausal disorders in women in the late reproductive period (perimenopause).
References
- Andreeva, E.N. “Efficacy and tolerability of drugs for the treatment of menopausal disorders.” Gynecology, 2(2005): 109–110.
- Lykhatskyi, P.G., Fira, L.S. “Red clover as a promising drug.” Medical Chemistry, 2(7) (2005): 108–110.
- Medicine of menopause // Ed. by V.P. Smetnik. Moscow (2006): 848 p.
- Tatarchuk, T.F., Yefymenko, O.A. “Principles of diagnostics, prevention and treatment of menopausal disorders.” Journal of Ukrainian Medical Elite, 4(10) (2009): 24–29.
- Tatarchuk, T.F., Yefymenko, O.A. “Modern view at hormone therapy.” Reproductive endocrinology, 2(4) (2012): 34–39.
- Beck, V., Unterrieder, E., Krenn, L., Kubelka, W., Jungbauer, A. “Comparison of hormonal activity (estrogen, androgen, and progestin) of standardized plant extract for large scale use in hormone replacement therapy.” J of Steroid Biochem & Molecular Biology 1831(2003): 1–10.
- C leve, A., Fritzemeier, K.H., Haendler, B., et al. “Pharmacology and clinical use of sex steroid hormone receptor modulators.” Handb Exp Pharmacol, 214(2012): 543–587.
- Ying, C., et al. “Growth inhibition of human endothelial cells by the phytoestrogen biochanin A, a metabolite of genistein.” Br J Nutr, 85(5) (20001): 615–620.
- M enopause State of the art / Ed. by Iole Di Francesco (2011): 540 p.
- Scheider, H.P.G., Heinemann, L.A.J., Rosemeir, H.P., et al. “The menopause rating scale (MRS): reliability of scores of menopausal compleants.” Climacteric, 3(2000): 59–64.
- Yureneva, S.V., Ilina, L.M., Mullabaeva, S.M. “Skin and sex hormones (effects of menopause and hormone replacement therapy).” Plastic surgery and cosmetology, 4(2011): 512–522.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Т. Ф Татарчук, А. О. Исламова, О. А. Ефименко
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.